Revolutionizing neurological care through the development of disease-modifying therapeutics
We are developing innovative disease-modifying therapeutics for patients with CNS disorders by leveraging proven mechanisms of action and neuroplastogens for their ability to promote neuroplasticity and neuro-rejuvenation.
Our lead program (PUR501) is a third generation 5-HT2A partial agonist, non-hallucinogenic neuroplastogen Novel Chemical Entity (NCE) with safe cardiovascular profile, followed by a second generation HDAC6 inhibitor NCE (PUR400 series).
Complementing our drug development efforts, PurMinds’ NeuroLab holds a Health Canada issued license for controlled substances that allows us to produce, process, sell and export a variety of psychedelic compounds, including a proprietary botanical Psilocybin program.
OUR MISSION is to develop best-in-class disease-modifying therapeutics for neurological conditions. We recognize that there is an urgent unmet need for innovative medicines for neurological disorders, as current treatments primarily focus on managing symptomology rather than addressing underlying issues. At PurMinds, our goal is to innovate medicines that target the root cause to prevent disease progression, improve long-term outcomes and, most importantly, enhance patients’ quality of life.
